The most commonly reported drug related adverse reactions of patients treated with dydrogesterone without estrogen treatment in clinical trials of indications are [[migraine]]s, [[headaches]], [[nausea]], menstrual disorders and [[mastodynia|breast pain/tenderness]],<ref name="MishellKirschbaum">{{cite book|author1=Daniel R. Mishell|author2=Thomas H. Kirschbaum|author3=C. Paul Morrow|title=1990 The Year Book of Obstetrics and Gynecology|url=https://books.google.com/books?id=0jYWNtrtD8MC|publisher=Year Book Medical}}</ref> bloating or weight gain.<ref>{{cite web |url=http://www.nhs.uk/Medicine-Guides/Pages/MedicineSideEffects.aspx?condition=Hormone%20replacement%20therapy&medicine=Dydrogesterone/Estradiol |title=Dydrogesterone/Estradiol (Generic Femoston 1/10mg tablets) |work=[[National Health Service (England)]]}}</ref>

 


 
The use of progestins, in particular [[medroxyprogesterone acetate]], in treating post-menopausal symptoms have been associated with increased risk of [[Thrombus|blood clots]]<ref>{{cite web |url=http://www.netdoctor.co.uk/womens-health/medicines/femoston.html |title=Femoston |work=NetDoctor.co.uk}}</ref> and [[breast cancer]] in a study carried out by the [[Women's Health Initiative]]. While the study did not involve dydrogesterone, it is possible, but not certain, that it too increases these risks.<ref>{{cite web |url=https://www.nhlbi.nih.gov/whi/whi_faq.htm |title=Questions and Answers About the WHI Postmenopausal Hormone Therapy Trials |work=[[Women's Health Initiative]]}}</ref>

 

